STAAR Surgical (NASDAQ:STAA) Major Shareholder Purchases $453,986.30 in Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. acquired 21,155 shares of STAAR Surgical stock in a transaction dated Tuesday, January 14th. The shares were bought at an average price of $21.46 per share, for a total transaction of $453,986.30. Following the transaction, the insider now owns 10,869,786 shares of the company’s stock, valued at approximately $233,265,607.56. The trade was a 0.20 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Thursday, January 16th, Broadwood Partners, L.P. purchased 8,221 shares of STAAR Surgical stock. The stock was bought at an average price of $21.50 per share, for a total transaction of $176,751.50.
• On Wednesday, December 18th, Broadwood Partners, L.P. bought 23,000 shares of STAAR Surgical stock. The stock was purchased at an average cost of $24.33 per share, for a total transaction of $559,590.00.
• On Monday, December 16th, Broadwood Partners, L.P. purchased 53,500 shares of STAAR Surgical stock. The shares were purchased at an average price of $24.24 per share, with a total value of $1,296,840.00.

STAAR Surgical Stock Up 0.6 %

NASDAQ:STAA traded up $0.14 during mid-day trading on Thursday, hitting $21.85. 531,485 shares of the stock traded hands, compared to its average volume of 732,698. STAAR Surgical has a 52 week low of $21.13 and a 52 week high of $52.68. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of 49.66 and a beta of 0.63. The firm’s 50 day moving average is $25.72 and its two-hundred day moving average is $32.16.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on STAA shares. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research report on Tuesday, January 7th. Canaccord Genuity Group lowered their price objective on shares of STAAR Surgical from $31.00 to $28.00 and set a “hold” rating for the company in a research report on Monday, December 9th. Finally, Stephens upgraded shares of STAAR Surgical to a “hold” rating in a report on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $42.83.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of STAA. Granite Investment Partners LLC purchased a new position in STAAR Surgical during the 2nd quarter valued at $17,237,000. Kayne Anderson Rudnick Investment Management LLC boosted its stake in shares of STAAR Surgical by 50.1% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 592,621 shares of the medical instruments supplier’s stock valued at $28,215,000 after purchasing an additional 197,717 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of STAAR Surgical by 411.7% in the third quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock worth $7,978,000 after purchasing an additional 172,779 shares during the last quarter. American Capital Management Inc. increased its stake in STAAR Surgical by 42.9% in the 3rd quarter. American Capital Management Inc. now owns 512,813 shares of the medical instruments supplier’s stock worth $19,051,000 after buying an additional 154,037 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in STAAR Surgical by 25.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 459,655 shares of the medical instruments supplier’s stock valued at $21,884,000 after buying an additional 94,422 shares in the last quarter. Hedge funds and other institutional investors own 96.70% of the company’s stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.